Stock A102460 REYON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials REYON Pharmaceutical Co., Ltd.

Equities

A102460

KR7102460003

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
13,780 KRW +1.17% Intraday chart for REYON Pharmaceutical Co., Ltd. +4.47% -16.69%
Mar. 21 REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 229,814 264,446 390,433 631,111 384,347 303,360
Enterprise Value (EV) 1 113,900 238,775 404,400 740,976 558,481 504,173
P/E ratio 172 x 44.6 x 97.9 x 116 x 53.2 x 84.8 x
Yield 3.6% 2.19% 0.9% 0.7% 0.69% -
Capitalization / Revenue 1.87 x 2.01 x 3 x 4.42 x 2.5 x 2.01 x
EV / Revenue 0.93 x 1.81 x 3.11 x 5.19 x 3.63 x 3.34 x
EV / EBITDA 26.3 x 19.9 x 65 x 119 x 62.2 x 76.9 x
EV / FCF -26.6 x -3.66 x -9.99 x -6.79 x -9.1 x -19.7 x
FCF Yield -3.76% -27.3% -10% -14.7% -11% -5.08%
Price to Book 1.03 x 1.2 x 1.7 x 2.58 x 1.6 x 1.23 x
Nbr of stocks (in thousands) 16,864 16,858 17,667 17,753 17,753 18,341
Reference price 2 13,627 15,686 22,100 35,550 21,650 16,540
Announcement Date 3/7/19 3/12/20 3/18/21 3/22/22 3/23/23 3/21/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 122,990 131,558 130,034 142,801 154,039 151,071
EBITDA 1 4,327 11,986 6,219 6,210 8,981 6,555
EBIT 1 2,460 7,898 1,654 1,545 4,448 1,773
Operating Margin 2% 6% 1.27% 1.08% 2.89% 1.17%
Earnings before Tax (EBT) 1 848.5 7,833 4,368 5,845 6,894 4,032
Net income 1 1,343 5,942 3,844 5,537 7,434 3,583
Net margin 1.09% 4.52% 2.96% 3.88% 4.83% 2.37%
EPS 2 79.02 352.0 225.8 305.4 407.0 195.0
Free Cash Flow 1 -4,286 -65,288 -40,494 -109,157 -61,372 -25,600
FCF margin -3.48% -49.63% -31.14% -76.44% -39.84% -16.95%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 490.2 343.1 200.0 250.0 150.0 -
Announcement Date 3/7/19 3/12/20 3/18/21 3/22/22 3/23/23 3/21/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 13,967 109,866 174,134 200,813
Net Cash position 1 115,914 25,671 - - - -
Leverage (Debt/EBITDA) - - 2.246 x 17.69 x 19.39 x 30.63 x
Free Cash Flow 1 -4,286 -65,288 -40,494 -109,157 -61,372 -25,600
ROE (net income / shareholders' equity) 0.6% 2.65% 1.7% 2.33% 3.02% 1.44%
ROA (Net income/ Total Assets) 0.52% 1.71% 0.35% 0.24% 0.58% 0.23%
Assets 1 259,446 347,649 1,099,351 2,281,521 1,287,218 1,592,610
Book Value Per Share 2 13,259 13,062 13,024 13,800 13,560 13,452
Cash Flow per Share 2 521.0 346.0 690.0 3,759 879.0 1,304
Capex 1 39,174 50,799 52,308 116,978 63,133 28,870
Capex / Sales 31.85% 38.61% 40.23% 81.92% 40.99% 19.11%
Announcement Date 3/7/19 3/12/20 3/18/21 3/22/22 3/23/23 3/21/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
REYON PHARMACEUTICAL CO., LTD. Stock REYON Pharmaceutical Co., Ltd.
-16.69% 184M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A102460 Stock
  4. Financials REYON Pharmaceutical Co., Ltd.